Johnson & Johnson

JNJ ·Healthcare, Drug Manufacturers - General, United States

Johnson & Johnson (JNJ)

Overview

Johnson & Johnson is one of the world's largest healthcare companies, headquartered in New Brunswick, New Jersey, and traded on the NYSE under the ticker JNJ. Founded in 1886, the company now operates as a pure-play healthcare business focused on pharmaceuticals and medical technology, employing roughly 138,000 people worldwide. For full-year 2025, J&J reported total revenue of $94.2 billion, up 6.0% from $88.8 billion in 2024, with net earnings of $26.8 billion. J&J is one of only two U.S.-based companies (alongside Microsoft) to hold a AAA credit rating, reflecting its financial scale and stability, and it ranked No. 48 on the 2025 Fortune 500 list.

What They Do & How They Make Money

J&J makes money by researching, manufacturing, and selling prescription medicines and medical devices to healthcare providers, patients, and payers around the world. It is important to note that the company most people associate with the "Johnson & Johnson" consumer brand — Band-Aids, Tylenol, Listerine, Neutrogena — no longer sits inside JNJ. In May 2023, J&J spun off its consumer health division as an independent public company, Kenvue Inc. (ticker KVUE), and by 2024 had fully divested its remaining stake. As a result, JNJ today is a two-segment biopharma and medical device company, not a consumer products company.

The Innovative Medicine (pharmaceutical) business generates revenue by discovering, developing, and commercializing prescription drugs, typically protected by patents that allow premium pricing for a period before generic or biosimilar competition erodes sales — a classic "patent cliff" revenue model. The MedTech business generates revenue by manufacturing and selling devices, implants, surgical instruments, and equipment used by hospitals and surgeons, sold both directly and through distributors, with revenue tied to procedure volumes, product innovation cycles, and device replacement/upgrade purchases. Across both segments, J&J invests heavily in R&D (a hallmark of the business) and grows both organically (new drug/device launches) and through bolt-on acquisitions.

Business Segments

J&J currently reports two operating segments:

Innovative Medicine (~64% of 2025 revenue, $60.4 billion, up 6.0% year-over-year): This is the pharmaceutical business, covering immunology, oncology, neuroscience, infectious diseases/vaccines, cardiovascular, pulmonary hypertension, and other specialty areas. Key franchises include immunology drugs Stelara and Tremfya, oncology drug Darzalex, and a growing pipeline of newer approvals such as Caplyta and Rybrevant. This segment carries higher margins than MedTech and has historically been the company's primary profit engine.
MedTech (~36% of 2025 revenue, $33.8 billion, up 6.1% year-over-year): This segment covers cardiovascular devices (electrophysiology, heart recovery), orthopedics (joint reconstruction, trauma, spine — largely through the DePuy Synthes brand), surgery (via Ethicon, making sutures, staplers, and energy devices), and vision care (contact lenses and cataract/refractive surgery products via Johnson & Johnson Vision).

J&J does not break out net income by segment in as much public detail as revenue, but Innovative Medicine has traditionally generated a larger share of operating profit than its revenue share would suggest, given higher gross margins typical of branded pharmaceuticals versus devices.

Competitors

Innovative Medicine (pharma) competitors:

Pfizer — broad overlap across vaccines, oncology, and biosimilars
Merck & Co. — oncology, immunology, vaccines
AbbVie — a direct rival in immunology (Humira/Skyrizi/Rinvoq compete with Stelara/Tremfya), neuroscience, and oncology
Bristol Myers Squibb — oncology and immunology
Amgen — immunology, oncology, nephrology, and biosimilars
Eli Lilly — immunology, diabetes, oncology, and neuroscience
Gilead Sciences — HIV, oncology, and virology
Roche/Genentech and Novartis — oncology and broad specialty pharma

MedTech (medical device) competitors:

Medtronic — orthopedics, cardiovascular, and neurotechnology; one of the largest pure-play device makers
Stryker — orthopedics, surgical instruments, and neurotechnology
Abbott Laboratories — cardiovascular devices and diagnostics
Boston Scientific — cardiovascular and endoscopy devices
Zimmer Biomet and Smith & Nephew — orthopedic implants, competing directly with DePuy Synthes

Indirect/adjacent competitors include generic and biosimilar manufacturers (e.g., Sandoz, Teva, Viatris) that erode branded-drug revenue after patent expiration, and large hospital-system group purchasing organizations that pressure device pricing.

Competitive Position

J&J's competitive moat rests on scale, R&D breadth, and diversification. It is one of the few companies with leading, profitable franchises in both pharmaceuticals and medical devices, which cushions the impact of a downturn or patent loss in any single product or business line — a structural advantage most single-segment pharma or device peers lack. Its balance sheet strength (AAA-rated, alongside only Microsoft among U.S. companies) gives it unusual flexibility to fund R&D, defend litigation, and pursue acquisitions through market cycles. In MedTech, its combination of orthopedics (DePuy Synthes), surgery (Ethicon), cardiovascular, and vision gives it one of the broadest device portfolios in the industry, competing at scale with Medtronic and Stryker. In pharma, it has built newer growth franchises (notably Tremfya and its oncology/Darzalex-led portfolio) specifically to offset the loss of exclusivity on its former blockbuster, Stelara, which has already begun losing share to biosimilars.

The company's most significant risks are threefold. First is the ongoing patent cliff dynamic inherent to branded pharma: Stelara's biosimilar erosion is already underway, and J&J must continuously replace lapsing exclusivity with new approvals — a race it has so far managed well but must keep winning. Second, MedTech growth, while solid, tends to run at lower margins and is more sensitive to hospital capital spending, procedure volumes, and competitive device pricing pressure from Medtronic, Stryker, and Abbott. Third, and most material near-term, is legacy litigation risk — primarily the massive talc/baby-powder litigation alleging its talcum products caused ovarian and other cancers. After three failed attempts to resolve the claims through a subsidiary bankruptcy (a strategy courts have repeatedly rejected as improper), J&J returned to the tort system; as of mid-2026 the company reached a proposed $5.5 billion settlement covering roughly 76,000 ovarian-cancer claims, though it requires 95% claimant acceptance to finalize, and tens of thousands of cases remain active in the federal MDL and state courts. J&J also carries residual liability tied to the opioid crisis, having agreed to pay roughly $5 billion as part of a broader industry settlement. These liabilities represent a real financial and reputational overhang, even though they have not, to date, impaired the company's core operating performance or its top-tier credit rating.